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Typical antipsychotics are characterized by extrapyramidal syndrome (EPS). Previous studies demon-
strated that typical antipsychotics could inhibit neuronal voltage-gated sodium channel (VGSC). How-
ever, EPS typically emerge only upon prolonged exposure. As a result, we examined effects of
haloperidol, a prototype typical antipsychotic, on neuronal VGSC upon incubation for varying duration.
Brieﬂy, VGSC currents were activated and recorded using a whole-cell patch-clamp technique in primary
culture of mouse cortical neurons. VGSC activity was inhibited by acute haloperidol exposure (for min-
utes), but enhanced in a time- and concentration-dependent manner by chronic haloperidol exposure
(for hours). The effects of chronic haloperidol were associated with increased expression of VGSC sub-
units as well as corresponding electrophysiological channel properties. In summary, we found enhanced
VGSC currents upon chronic haloperidol exposure in cortical neurons in contrast to inhibition by acute
haloperidol exposure. Such a results may contribute to EPS of typical antipsychotics.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Typical antipsychotics exempliﬁed by haloperidol form the
basis of psychosis treatment [1], and are occasionally used to man-
age Tourette’s syndrome [2], nausea, and vomiting [3]. These
agents have high afﬁnity for D2 dopamine receptors [4]. A major
limitation of typical antipsychotics is extrapyramidal syndrome
(EPS) [5,6].
The pharmacological actions of haloperidol, including the EPS,
were previously thought to be mainly mediated by blockade of
dopamine receptors [7,8]. However, recent research also impli-
cated multiple ion channels. For example, typical antipsychotics
(e.g., haloperidol and pimozide) could block L-type [9] and T-type
calcium channels [10]. Inhibition of calcium-activated potassium
channels has also been found for phenothiazine-derivatives
[11,12]. Off-target effects at the hERG potassium channel have
linked to cardiac liability of several antipsychotics [13].
Voltage-gated Na+ channels (VGSCs) consist of pore-forming a-
subunits (220–260 kDa) and auxiliary b-subunits (32–36 kDa) [14].
VGSCs regulate the regeneration and propagation of actionpotentials (AP) by mediating the inward Na+ current in excitable
cells [15,16]. Knockout of ﬁbroblast growth factor homologous fac-
tors in mice inhibits the APs via modifying electrophysiological
properties of VGSCs [17]. VGSCs also affect the resting potential
of neurons, and the threshold for AP generation [18].
Previous studies demonstrated that acute haloperidol treat-
ment could inhibit neuronal VGSCs [19]. In the present study, we
examined the effects of haloperidol (0.1–25 lM) on VGSC in
cultured mouse cortical neurons upon varying exposure time (4–
48 h) with patch-clamp. Effects on VGSC subunits were examined
at the protein levels.2. Materials and methods
2.1. Cortical neuron culture
The primary culture of mouse cortical neurons was established
using 14-day-old (E14) C57 BL/6J mouse embryos, as previously
reported [20]. Brieﬂy, cerebral cortices (containing no hippocam-
pus) were trypsinized for 2 min with 4-ml 0.25% trypsin (Invitro-
gen) at 37 C and then interrupted with 0.5-ml fetal bovine
serum (HyClone). Cells were collected by centrifugation for
10 min at 900g, re-suspended in minimum essential medium
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treated with 12.5 lg/ml poly-D-lysine (Sigma) at 1  106 per well.
Glutamine (Sigma; 2 mM) and 2% B-27 supplement were added
into the neurobasal medium immediately before use. Cells were
incubated in 2-ml culture medium in 35-mm petri dishes at
37 C in 5% CO2/95% air. Half of the culture medium was changed
every 3 days. A selective inhibitor of DNA synthesis, arabinosylcy-
tosine C (4 lM), was added to the medium on day 3 for 24 h to
eliminate glial cells. All experiments were performed after
8–12 days. The animals used in this study were housed and treated
according to the guidelines for care and use of experimental ani-
mals of the Ethics Committee of Shantou University Medical
College.
2.2. Electrophysiological recording
Electrophysiological recording was carried out as previously
reported [20]. The bath solution composed of 140 mM NaCl,
5 mM KCl, 1 mM MgCl2, 2 mM CaCl2 10 mM HEPES, 4 mM TEA-
Cl, 0.1 mM CdCl2 and 10 mM glucose (pH adjusted to 7.3 with
NaOH) for whole-cell recording of voltage-gated Na+ currents.
The pipette solution contained 145 mM CsCl, 1 mM MgCl2, 1 mM
CaCl2, 1 mM EGTA, 10 mM HEPES, and 5 mM ATP-Na2 (pH adjusted
to 7.3 with CsOH). Patch pipettes were pulled to a tip resistance of
2–5 MO from a borosilicate glass capillary using a P-97 micropi-
pette puller (Sutter Instrument). Voltage-clamp recording was per-
formed using an EPC-10 ampliﬁer (HEKA). Series resistance was
compensated by 70–90%. Data were digitized at 200 kHz. Neurons
were held at 80 mV and then depolarized to 100 mV with 5-mV
steps (each 20 ms) and 0.5 Hz frequency to examine the activation
of VGSCs. Na+ currents were recorded at 0 mV after prepulse from
100 mV to 30 mV for 40 ms with 5-mV steps to examine the
inactivation of VGSCs.
APs were recorded in a current clamp mode to measure the
threshold and ﬁring rate of the spike. Cells were held at 0 pA,
and APs were elicited by depolarizing currents ranging from
50 pA to 70 pA (120 ms) with increments of 10 pA or a ramp cur-
rent of 0–500 pA (100 ms). The external solution contained
140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 0.1 mM CdCl2, 1 mM CaCl2,
and 10 mM HEPES (pH adjusted to 7.3 with NaOH). The pipette
solution contained 140 mM KCl, 10 mM EGTA, 5 mM Mg-ATP,
and 5 mM HEPES (pH adjusted to 7.3 with KOH). All experiments
were performed at 23–25 C.
2.3. Drug application
In acute experiments, cells were exposed to haloperidol at 0.1–
250 lM in extracellular solution for 5 min. In chronic experiments,
cells were exposed to haloperidol (25–100 lM) for 2–48 h. The D2
receptor agonist bromocriptine (10 lM) was present in some
experiments for 1 h before and during haloperidol (25 lM 24 h)
treatment. Brain derived neurotrophic factor (BDNF; 30 ng/ml)
was present in some experiment with haloperidol (25 lM 24 h).
2.4. Immunoblot
Membrane fraction was prepared using discontinuous sucrose
gradient centrifugation. Brieﬂy, whole-brain lysate in 0.32 M
sucrose/5 Mm Tris (pH 7.4) were layered onto 1.2 M sucrose/5 mM
Tris (pH 7.4), and centrifuged at 10,000g for 30 min. The 0.8 M to
1.2 M sucrose interface was collected, diluted twofold with 0.8 M
sucrose/5 mM Tris (pH 7.4), and centrifuged at 20,000g for
20 min. The resulting pellet was re-suspended in RIPA buffer
containing 25 mM Tris, 150 mM NaCl, 1 mM EDTA, and 2% Triton
X-100 (pH 7.4), and centrifuged at 20,000g for 20 min to yield
the ﬁnal membrane preparation (supernatant). Complete proteaseinhibitor (Roche) was included during the entire procedure. Mem-
brane preparation (100-mg protein) was fractionated by SDS–PAGE,
and transferred onto a nitrocellulose membrane (Millipore). The
membrane was blocked in 5% nonfat milk and then incubated with
a mouse anti-pan Nav antibody (1:200; Alomone) overnight at
4 C, followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (anti-mouse 1:1,000; Sigma) and
visualization through chemiluminescence.
2.5. Statistical analysis
Data are expressed as mean ± SEM, and analyzed using Origin
software (Origin Lab Corporation, Northampton, USA) and SPSS
15.0 (SPSS Inc., USA). The normative Na+ current amplitudes,
current density (pA/pF), current concentration dependency, time
dependency, and protein expression level were evaluated and
compared using one-way ANOVA followed by SNK test. The activa-
tion and inactivation of VGSCs, thresholds, and the ﬁring rate of
spikes were analyzed with Student’s t-test.
3. Results
The Na+ currents were completely blocked with TTX (300 lM)
(Fig. 1A).
3.1. Effects of haloperidol on Na+ currents
3.1.1. Acute vs. chronic exposure
Acute exposure to haloperidol (for 5 min) decreased the Na+
currents by 22% ± 2.27%, 52% ± 2.52%, and 85.82% ± 0.85% at 10,
25, and 250 lM (Fig. 1B and C; IC50 = 19.38 M). The inhibitory
effect of haloperidol was reversible upon washout (Fig. 1B).
An inward current with fast activation and inactivation was
elicited by depolarization steps from 80 mV of the holding poten-
tial and recorded at 200 kHz of the sampling frequency (Fig. 1D).
Haloperidol treatment for 24 h signiﬁcantly enhanced the volt-
age-gated Na+ currents at most activated potentials (Fig. 1E and
F). The increase of Na+ currents was 57% ± 4.48%, 143% ± 5.42%
and 145% ± 4.27% at 10, 25 and 100 lM, respectively. The peak cur-
rents at 20 mV plotted against haloperidol concentration indi-
cated that the enhancement was concentration-dependent
(Fig. 1F).
3.2. Time-dependent effects of haloperidol on Na+ currents
Upon haloperidol treatment (25 lM) for 30 min, the Na+ cur-
rents were increased after 24–48 h, but not 1–8 h (Fig. 1G). Halo-
peridol treatment (100 lM) for 30 min increased Na+ currents
after 8–24 h but not earlier; neuronal death was noted after 48 h.
3.4. Effects of haloperidol on Na+ channel kinetics
Fig. 2 is representative conductance-voltage curve, ﬁtted using
the Boltzmann equation (Fig. 2A). Channel inactivation was
reﬂected using the peak currents at 0 mV of the test voltage, nor-
malized using the maximal current (Fig. 2B). Normative currents
were plotted to the pre-pulse voltage, while the current–voltage
curves were ﬁtted using the Boltzmann equation (Fig. 2B).
Acute perfusion with haloperidol (25 lM) accelerated the inac-
tivation of Na+ channels (Fig. 2A), but did not affect activation
properties (Fig. 2B). In contrast, chronic haloperidol treatment
accelerated the activation of Na+ channels, but did not affect inac-
tivation properties (Fig. 2C and D).
Immunoblot assay of VGSCs using a pan-antibody in the cell
membrane (Fig. 3A and B) showed that 24-h haloperidol treatment
Fig. 1. Effects of haloperidol on Na+ currents. (A) Representative recording of whole-cell currents in the presence or absence of TTX (300 lM). (B) Representative recording of
whole-cell Na+ currents upon acute perfusion with haloperidol (10, 25 or 250 lM). (C) The concentration–response relationship for haloperidol inhibition of the Na+ currents;
IC50 = 19.38 lM. (D) Recording of whole-cell Na+ currents from 80 to 100 mV upon 24-h exposure to haloperidol (25 and 100 lM). (E) Current–density–voltage relationship
upon 24-h exposure to haloperidol (0.1–100 lM). (F) Concentration-dependent effects of 24-h haloperidol treatment (0.1–100 lM) on Na+ currents; EC50 = 10.64 lM). (G)
Time-dependent effects of haloperidol (25 and 100 lM) on Na+ currents. Current data were normalized by control and expressed as percentage of the control. ⁄P < 0.05
compared with the control (one-way ANOVA followed by SNK).
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56% ± 3.7% (P < 0.05).3.3. Effects of bromocriptine and BDNF
Pretreatment with bromocriptine (10 lM) or BDNF (30 ng/ml),
starting from 30 min prior to haloperidol treatment blocked the
haloperidol effects on Na+ currents (Fig. 3C and D). However,
neither the activation nor inactivation of the Na+ channels was
signiﬁcantly affected by bromocriptine or BDNF (Fig. 3E and F).3.4. Effects of haloperidol on the amplitude and threshold of the spike
Acute perfusion with haloperidol (25 lM) abolished the AP in
cortical neurons (Fig. 4A–D). Haloperidol treatment (25 lM) for
24-h decreased the threshold of the spike (Fig. 4E–G), and
increased the ﬁring rate (Fig. 4H–J).4. Discussion
Major ﬁndings of the current study include: (1) acute haloperi-
dol exposure inhibits VGSC activity by accelerating the inactivation
of Na+ channels in a concentration-dependent manner; (2) chronic
haloperidol exposure enhances voltage-gated Na+ currents in a
time- and concentration-dependent manner by accelerating the
activation of Na+ channels. Another ﬁnding is chronic haloperidol
potentiation on VGSCs can be counteracted by bromocriptine and
BDNF.4.1. Mechanism of the effects of haloperidol on Na+ currents
Acute haloperidol shifted the steady-state inactivation curve to
the left. Channel activation was not affected. The inhibitory effect
of haloperidol is largely reversible upon washout. Perhaps more
time was needed for complete recovery of the peak amplitude of
Na+ currents.
Effects of chronic haloperidol treatment on cortical neurons are
mediated by D2 receptor inhibition [21]. The D2 receptor agonist
bromocriptine blocked haloperidol-induced increases of Na+ cur-
rents. Previous studies demonstrated that bromocriptine could
successfully treat Neuroleptic malignant syndrome [22,23], and
protect neurons against 6-hydoxydopamine damage via its hydro-
xyl free radical scavenging activity and inhibition of dopamine
turnover [24]. Alternatively, bromocriptine’s effects might be
attributable to GPCR-mediated modulation of channel function.
Indeed, dopamine receptor activation has been shown to inﬂuence
both sodium and calcium channel function indirectly, possibly by
modulating channel phosphorylation [25]. Regulation of sodium
channel activity has been reported in certain neuronal populations
following D2 receptor stimulation [26]. All together, our results
suggest that VGSC alterations in neurons likely contribute to halo-
peridol-induced EPS, which could be relieved by bromocriptine-
induced VGSCs inhibition.
Previous study had highlighted the therapeutic potential of
BDNF in a range of CNS disorders – including Alzheimer’s disease,
stroke and depression [27]. The results from the current study
showed that BDNF could block haloperidol-induced increases of
Na+ currents, raising the possibility that BDNF could protect
against haloperidol-induced EPS.
Fig. 2. Effects of haloperidol on Na+ channel kinetics. (A) Voltage-dependent activation upon acute perfusion with haloperidol (25 lM) vs. blank control groups. (B) Voltage-
dependent fast-inactivation upon acute perfusion with haloperidol (25 lM) vs. blank control. (C) Voltage-dependent activation upon 24-h haloperidol treatment (25 lM) vs.
the control. (D) Representative inactivation properties, and voltage-dependent inactivation upon 24-h haloperidol treatment (25 lM) vs. the control.
Fig. 3. Effects of haloperidol on VGSCs expression and effects of bromocriptine and BDNF on haloperidol’s augmentation of Na+ currents. (A) Representative immunoblot of
Nav channels protein in the cell membrane upon 24-h haloperidol exposure (25 lM) group vs. blank control. (B) Summary of haloperidol effects on VGSCs expression. Values
represent three separate experiments performed in duplicate. (C) An illustration of the recording curves of whole-cell Na+ currents from 80 mV to 100 mV in the control and
haloperidol (25 lM, 24 h), haloperidol + bromocriptine, and haloperidol + BDNF groups. (D) Normalized peak currents in the control and haloperidol (25 lM, 24 h),
haloperidol + bromocriptine, and haloperidol + BDNF groups. (E) Voltage-dependent activation curves in the control and haloperidol (25 lM, 24 h), haloperidol + bromo-
criptine, and haloperidol + BDNF groups. (F) Voltage-dependent inactivation curves in the control and haloperidol (25 lM, 24 h), haloperidol + bromocriptine, and
haloperidol + BDNF groups. ⁄P < 0.05 compared with the control and/or haloperidol (25 lM, 24 h) group (one-way ANOVA followed by SNK).
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Fig. 4. Effects of haloperidol on action potentials. (A) Representative recording showing traces of action potentials. (B) Haloperidol perfusion (25 lM) abolished the action
potential. (C and D) Representative spike elicited by a ramp depolarizing current in the blank control (C) vs. haloperidol (25 lM) (D). (E and F) Representative recordings of
action potentials, and decrease of AP threshold by 24-h haloperidol treatment (25 lM). (G) Summary of haloperidol effects (25 lM for 24 h) on AP threshold (⁄P < 0.05, n = 10/
group). (H and I) Representative recordings of ﬁring rate of AP in response to current injection (500 pA, 1 s) in the control neuron vs. upon haloperidol treatment (25 lM for
24 h). (J) Summary of haloperidol effects (25 lM for 24 h) on the ﬁring rate (⁄P < 0.05, n = 8/group). Statistical analysis was carried out with Student’s t-test.
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currents
The selection of haloperidol concentration (0.1–25 lM) for the
current study was based on concentrations reported in the brain
tissue of patients, especially tardive dyskinesia (TD) patients, dur-
ing long-term therapeutic treatment with haloperidol [21,28].
Augmentation of Na+ currents in injured neurons increases the
consumption of energy used to maintain the Na+ gradient across
the plasma membrane [29]. Therefore, haloperidol ampliﬁcation
of Na+ currents in cortical neurons may reduce neuronal survival
in injuries and diseases of the CNS. An exempliﬁcation of this is a
spike that was recorded using the current-clamp technique in our
experimental conditions, which showed that the AP amplitude
was signiﬁcantly higher in the haloperidol (25 lM, 24 h) treat-
ment group after using a ramp pulse current (0–500 pA) to mea-
sure AP. This result is consistent with the current density
recording results showing that haloperidol increases neuronal
excitability. Previously studies showed that haloperidol could
promote neuronal death by increasing Ca2+ entry into the neu-
rons [30–32]. An increase in AP amplitude and ﬁring rate may
enhance Ca2+ inﬂux through voltage-gated Ca2+ channels during
the spike, and exacerbate the damage of injured neurons induced
by Ca2+ overload. Excitotoxicity resulting from the excessive
release of excitatory transmitters from the presynaptic mem-
brane, putatively caused by increased AP amplitude and ﬁring
rate, is involved in many brain diseases and injuries [32,33].
Based on the ﬁndings of increased AP ﬁring rate and amplitude,we speculate that haloperidol could promote the release of
neurotransmitters from the presynaptic terminal and exhibit
neurotoxic effects on the CNS.
In summary, our results suggest that haloperidol enhances the
activity of VGSCs in cortical neurons upon prolonged exposure in
contrast to previous reports of channel inhibition upon acute hal-
operidol exposure, and both bromocriptine and BDNF counteract
the VGSC potentiation induced by haloperidol. We speculate that
such time-dependent effects contribute to the time dependency
of both therapeutic effects and side effects of haloperidol. In
addition, the ﬁndings prompt the therapeutic potential of BDNF
on haloperidol-induced EPS.
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